[go: up one dir, main page]

SE9601396D0 - New therapeutic treatment 2 - Google Patents

New therapeutic treatment 2

Info

Publication number
SE9601396D0
SE9601396D0 SE9601396A SE9601396A SE9601396D0 SE 9601396 D0 SE9601396 D0 SE 9601396D0 SE 9601396 A SE9601396 A SE 9601396A SE 9601396 A SE9601396 A SE 9601396A SE 9601396 D0 SE9601396 D0 SE 9601396D0
Authority
SE
Sweden
Prior art keywords
therapeutic treatment
new therapeutic
inositols
osmolyte
taurine
Prior art date
Application number
SE9601396A
Other languages
English (en)
Swedish (sv)
Inventor
Dieter Haeussinger
Original Assignee
Dieter Haeussinger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dieter Haeussinger filed Critical Dieter Haeussinger
Priority to SE9601396A priority Critical patent/SE9601396D0/xx
Publication of SE9601396D0 publication Critical patent/SE9601396D0/xx
Priority to CA002251071A priority patent/CA2251071A1/fr
Priority to PCT/EP1997/001861 priority patent/WO1997038685A1/fr
Priority to JP9536745A priority patent/JP2000508651A/ja
Priority to EP97919356A priority patent/EP0946167A1/fr
Priority to AU23860/97A priority patent/AU2386097A/en
Priority to US08/878,557 priority patent/US5880098A/en
Priority to NO984759A priority patent/NO984759L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE9601396A 1996-04-12 1996-04-12 New therapeutic treatment 2 SE9601396D0 (sv)

Priority Applications (8)

Application Number Priority Date Filing Date Title
SE9601396A SE9601396D0 (sv) 1996-04-12 1996-04-12 New therapeutic treatment 2
CA002251071A CA2251071A1 (fr) 1996-04-12 1997-04-14 Utilisation d'un osmolyte dans la preparation d'un medicament destine a traiter des complications resultant de l'ischemie
PCT/EP1997/001861 WO1997038685A1 (fr) 1996-04-12 1997-04-14 Utilisation d'un osmolyte dans la preparation d'un medicament destine a traiter des complications resultant de l'ischemie
JP9536745A JP2000508651A (ja) 1996-04-12 1997-04-14 虚血を原因とする合併症を治療する医薬を製造するためのオスモライトの使用
EP97919356A EP0946167A1 (fr) 1996-04-12 1997-04-14 Utilisation d'un osmolyte dans la preparation d'un medicament destine a traiter des complications resultant de l'ischemie
AU23860/97A AU2386097A (en) 1996-04-12 1997-04-14 Use of an osmolyte in the preparation of a medicament for treating complicati ons resulting from ischemia
US08/878,557 US5880098A (en) 1996-04-12 1997-06-19 Therapeutic treatment
NO984759A NO984759L (no) 1996-04-12 1998-10-12 Anvendelse av en osmolytt ved fremstilling av et medikament for behandling av komplikasjoner forÕrsaket av iskemi

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9601396A SE9601396D0 (sv) 1996-04-12 1996-04-12 New therapeutic treatment 2

Publications (1)

Publication Number Publication Date
SE9601396D0 true SE9601396D0 (sv) 1996-04-12

Family

ID=20402175

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9601396A SE9601396D0 (sv) 1996-04-12 1996-04-12 New therapeutic treatment 2

Country Status (7)

Country Link
EP (1) EP0946167A1 (fr)
JP (1) JP2000508651A (fr)
AU (1) AU2386097A (fr)
CA (1) CA2251071A1 (fr)
NO (1) NO984759L (fr)
SE (1) SE9601396D0 (fr)
WO (1) WO1997038685A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080788A (en) * 1997-03-27 2000-06-27 Sole; Michael J. Composition for improvement of cellular nutrition and mitochondrial energetics
BE1012495A3 (fr) 1999-03-02 2000-11-07 Messadek Jallal La glycine-betaine pour son usage antithrombotique.
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
ATE247981T1 (de) 1999-06-12 2003-09-15 Bitop Ag Proteinenthaltende pharmazeutische zubereitung
EP1272201B1 (fr) * 2000-04-12 2004-11-24 Bitop Aktiengesellschaft Für Biotechnische Optimierung Utilisation de solutes compatibles en tant que substances aux proprietes de piegeage de radicaux
JP5084089B2 (ja) * 2001-06-14 2012-11-28 大塚製薬株式会社 医薬組成物
BE1015608A6 (fr) 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
DE10330768A1 (de) * 2003-07-07 2005-02-24 bitop Aktiengesellschaft für biotechnische Optimierung Verwendung von aus extremophilen Bakterien gewonnenen Osmolyten zur Herstellung von inhalierbaren Arzneimitteln zur Prophylaxe und Behandlung pulmonaler und kardiovaskulärer Erkrankungen, sowie eines Osmolyte als Wirkstoffbestandteil enthaltende Inhalationsvorrichtung
RU2259822C1 (ru) * 2004-02-27 2005-09-10 ЗАО "НПО ПЦ Биофизика" Противоишемическое средство, обладающее противоаритмическим и противоатерогенным действием, и способ его применения
WO2006050581A2 (fr) * 2004-11-10 2006-05-18 Jallal Messadek Betaine en tant qu'agent de lutte contre des maladies transmises par des arthropodes ou des moustiques
WO2006086856A1 (fr) 2005-02-15 2006-08-24 Messadek, Jallal Compositions therapeutiques combinees et leurs procedes d’utilisation
CN101180073A (zh) 2005-04-27 2008-05-14 贾拉尔·梅萨德克 胰岛素组合
DE102008006780A1 (de) * 2008-01-30 2009-08-06 Bitop Ag Verwendung von Tetrahydropyrimidinen
JP2021147393A (ja) * 2020-03-13 2021-09-27 ロート製薬株式会社 酸化ストレス抑制剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE464059C (sv) * 1988-09-15 1997-06-02 Perstorp Ab Användning av inositoltrifosfat för framställning av läkemedel
JP2642198B2 (ja) * 1989-08-24 1997-08-20 元庸 村上 胃粘膜障害治療剤
SE8904355D0 (sv) * 1989-12-21 1989-12-21 Perstorp Ab Medicament
AU7584891A (en) * 1990-03-19 1991-10-21 Brigham And Women's Hospital Treatment of osmotic disturbance with organic osmolytes
US5312839A (en) * 1991-03-05 1994-05-17 Regents Of The University Of California Compounds and method for protection of cells and tissues from irreversible injury due to lactic acidosis
CH686870A5 (fr) * 1992-09-18 1996-07-31 Pasteur Merieux Serums Vacc Solution de perfusion, de conservation et de reperfusion d'organes.
US5582839A (en) * 1995-04-18 1996-12-10 Nutrition 21 Magnesium taurate and other mineral taurates

Also Published As

Publication number Publication date
EP0946167A1 (fr) 1999-10-06
NO984759D0 (no) 1998-10-12
WO1997038685A1 (fr) 1997-10-23
JP2000508651A (ja) 2000-07-11
AU2386097A (en) 1997-11-07
NO984759L (no) 1998-10-12
CA2251071A1 (fr) 1997-10-23

Similar Documents

Publication Publication Date Title
SE9601396D0 (sv) New therapeutic treatment 2
EP1537861A3 (fr) Utilisation de composés aminothiols pour le traitement de la xerostomie induite par des agents thérapeutiques ou la radiation
HU912359D0 (en) The use of flupirtine active agents for treating muscle-tension
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
BR9610838A (pt) Processo para tratar um indivìduo tendo uma condição patológica envolvendo neovascularização.
ES2174953T3 (es) Composiciones dermatologicas que contienen peroxido de benzoilo y un compuesto que reduce la irritacion de la piel.
ATE461698T1 (de) Gaba-analoga zur verhütung und behandlung gastrointestinaler beschwerden
EP0160703A4 (fr) Appareil therapeutique produisant un champ magnetique.
NZ335981A (en) Ketobenzamides as calpain inhibitors
PL310474A1 (en) Application of rilusole in treating neuro-aids diseases
EP1712236A3 (fr) Dérivés du tetracycline destinés au traitement de l'acné
DK71387A (da) Terapeutisk middel til behandling af psoriasis
IE820311L (en) Tetrahydronaphthalene and indane compounds
SE9601395D0 (sv) New therapeutic treatment 1
ATE273702T1 (de) Eisenverbindungen, zusammensetzungen, herstellungsverfahren und verwendungen davon
PT1007055E (pt) Utilizacao de amifostina
CA2144728A1 (fr) Methode de traitement symptomatique du syndrome premenstruel avec de la vitamine d ou de la vitamine d et du calcium
ATE293972T1 (de) Behandlung von chronischen schmerzen
ATE149840T1 (de) Behandlung von leberkrebs
ES2180643T3 (es) Procedimiento para tratar la disfuncion cognitiva.
DK0984787T3 (da) Anvendelse af lavmolekylære hepariner til forebyggelse og behandling af hjerneødemer
EA199900174A1 (ru) Способ лечения биполярного расстройства
DE3585312D1 (de) Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyrido(1,2-a)pyrimidin-3-carboxamid zur vorbeugung und behandlung von gastrointestinalschaeden.
DK1133297T3 (da) Ny terapeutisk anvendelse af 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin
UA32151A (uk) Склад для лікування псоріазу